TP53 and myelodysplastic syndrome: Besides MDS/AML, a pan-cancer analysis of TP53 mutations and related metabolic pathways showed that TP53 plays a key role in glycolysis regulation by suppressing the AKT/mTOR and NF-kB signaling pathways and the expression of related genes, such as PFKP and SLC16A3 [24].